Core myopathies …

Developmental Malformations

Updated 12.14.2024
Released 09.18.1994
Expires For CME 12.14.2027

Core myopathies

Authors: Haluk Topaloglu MD, Bita Poorshiri MD

See Contributor Disclosures

Editor: Harvey B Sarnat MS MD FRCPC

Core myopathies

In This Article

Quick Link

Introduction

Overview

Congenital myopathies represent a clinically and genetically heterogeneous group of early-onset neuromuscular diseases with characteristic, but not always specific, histopathological features. They often present with stable or slowly progressive truncal and proximal weakness. The classification of congenital myopathies was initially based on pathological phenotype and clinical manifestations but has recently been based on their variable genetic basis (106). It is often not possible to make a diagnosis solely based on clinical findings. Additional extraocular, respiratory, distal involvement, scoliosis, and distal laxity may provide clues (24).

The “core myopathies” collectively represent the most common form of congenital myopathies, and the name pathologically corresponds to histochemical appearance of focally reduced oxidative enzyme activity and myofibrillar changes on ultrastructural studies. Subtypes of core myopathies are determined by the location, shape, size, and number of cores. Centrally located cores are called central core disease. Numerous small scattered cores are commonly found in multinucleated disease (MmD). Irregular areas of myofibrillar disarray with patchy oxidative staining and a lack of ATPase activity have been identified, and this has been called as dust nucleus disease (DuCD) (39).

Because of the clinical, pathological, and molecular overlaps, central core disease and multiminicore disease will be discussed together. Of note, cores can be seen in combination with nemaline rods and are termed “core-rod myopathies,” which is associated with a variety of different mutations (18).

Mutations in the skeletal muscle ryanodine receptor 1 (RYR1) gene are associated with dominantly inherited central core disease and subgroups of recessively inherited multiminicore disease, centronuclear myopathy (CNM), and congenital fiber type disproportion. Malignant hyperthermia susceptibility trait is a dominantly inherited allelic trait and is described as a pharmacogenetic predisposition to severe and potentially life-threatening reactions in response to halogenated anesthetic agents and depolarizing muscle relaxants.

RYR1-related malignant hyperthermia susceptibility is allelic to central core disease and has also been described as a common cause of induced and episodic phenotypes such as exertional rhabdomyolysis or periodic paralysis, which is present throughout life. Late-onset presentations in the adulthood period highlight the relevance of congenital myopathies for adult neuromuscular practice.

Mutations in another gene, CACNA1S, inherited in an autosomal dominant manner, can cause malignant hyperthermia in patients with core myopathy (08).

A number of distinct phenotypes are seen in multiminicore disease, which is most commonly caused by recessive mutations in the RYR1 and SEPN1 genes. It has been linked to dominant mutations in the gene for beta-myosin heavy chain protein (MYH7) and autosomal recessive mutations of titin (TTN). Recessive mutations of satellite cell gene (MEGF10) are defined in patients with early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARRD). A few other genes have also been identified within this group (Table 1).

Key points

	• Core myopathies represent the most common form of congenital myopathies and are characterized pathologically by the absence of oxidative enzyme activity in the central area of myofibers representing mitochondrial depletion.
	Central core disease and multiminicore disease are the most common congenital myopathy forms.
	• Central core disease is dominantly inherited in most cases. Recessive central core disease is less common and often more severe, and it presents at a younger age. Most cases of central core disease are due to mutations in the gene for ryanodine (RYR1), a skeletal muscle calcium channel receptor.
	• RYR1-related malignant hyperthermia susceptibility trait is an allelic condition to central core disease. RYR1 mutations may present in the adulthood period as induced and episodic phenotypes, such as exertional rhabdomyolysis and periodic paralysis.
	• Major causes of multiminicore disease are recessively inherited mutations in the genes encoding selenoprotein N (SEPN1) and RYR1. Other rare causes are recessive mutations in TTN, MEGF10, and CACNA1S, and dominant mutations in MYH7 and CACNA1S. There are more (Table 1).
	• Also, mutations in CACNA1S, inherited in an autosomal dominant manner, can cause malignant hyperthermia in patients with multiminicore disease.
	• There may be a continuum between multiminicore disease and central core disease; patients and carriers with certain missense mutations in RYR1 are at risk of malignant hyperthermia.

Historical note and terminology

In 1956, Magee and Shy described “a new congenital nonprogressive myopathy” characterized by a distinctive microscopic appearance on skeletal muscle biopsy (62). It was the first recognition of the congenital myopathies, the diagnosis of which was based on the distinct structural or histochemical changes in biopsied skeletal muscle, as a distinct group of diseases.

This disorder was then named central core disease (43), and an absence of oxidative enzyme and phosphorylase reactivity in the cores were demonstrated on muscle biopsy in these patients (26).

In 1971, Engel and colleagues described a patient with multiple small cores within muscle fibers (28), which were later renamed as “multicores,” “minicores,” “focal loss of cross-striation,” “target-like lesions,” and “miniature cores;” multiminicore disease is now the preferred terminology (32).

Clinical manifestations

Presentation and course

There is a wide clinical spectrum of core myopathies, with severity ranging from mild to severe. Hypotonia, joint laxity, delayed motor milestones, hip girdle or axial weakness, and congenital hip dysplasia may be among early clinical presentations. Arthrogryposis represents the severe end of the spectrum. There may be variability even within the same family; some of the individuals are asymptomatic and others present with hyperkalemia, exertional myalgia, rhabdomyolysis or periodic muscle stiffness, and paralysis.

Typical central core disease patients present with mild and symmetrical weakness, hypotonia, and delayed motor milestones, and although late, achieve independent ambulation. The course is usually nonprogressive or slowly progressive. Patients presenting with severe neonatal weakness, arthrogryposis, and respiratory failure require early respiratory support and corrective scoliosis surgery. More significant respiratory muscle weakness is seen in infants with recessive core disease (70; 87; 02). Extraocular muscles are spared in the dominant forms. Because of musculoskeletal deformities including congenital hip dislocation, kyphoscoliosis, pes cavus, pes planus, and thoracic deformities, patients are frequently referred from orthopedic clinics. Heart disease is not considered as a part of the typical “core myopathy” spectrum. Some cardiac abnormalities described include mitral valve prolapse, arrhythmias, and asymptomatic right bundle branch block (96). Intelligence is generally normal in central core disease.

Genetic resolution of core myopathies has further led to “mutation-specific” clinical presentations and phenotype-genotype correlations. The availability of next-generation sequencing (NGS) techniques has improved the detection rate for mutations and expanded the clinical spectrum (25; 02; 10).

Central core disease is associated mainly with dominant RYR1 mutations, and multiminicore disease is genetically a more heterogenous condition (54).

The central core disease is associated mainly with dominant RYR1 mutations, whereas the multimonitor disease is genetically more heterogeneous (53).

Dominantly inherited RYR1-related central core disease is characterized by mild to moderate muscle weakness presenting from infancy to childhood. Congenital hip dislocation, scoliosis, and generalized joint laxity are common. In contrast to the recessive forms with a more severe clinical phenotype, there is no extraocular muscle involvement. Bulbar, respiratory, and cardiac involvement is uncommon. Myalgia may be prominent. Central core disease tends to be stable over long periods with a possible progression in adulthood, and due to intrafamilial variability, there may be a delay in diagnosis.

Malignant hyperthermia is a disorder of calcium metabolism. Central core disease is associated with an increased risk of malignant hyperthermia. Most patients with malignant hyperthermia have normal muscle biopsy features, and less than 30% of the patients with central core disease have malignant hyperthermia susceptibility (57). Two well-known malignant hyperthermia-related syndromes are King-Denborough syndrome and Native American myopathy (NAM).

The association between malignant hyperthermia and central core disease patients was first described in 1973 and has since been confirmed in many other reports (19; 35; 96).

King-Denborough syndrome is characterized by facial and skeletal dysmorphism, malignant hyperthermia susceptibility, and myopathy (85; 16; 23). All genetically solved patients to date are due to RYR1 mutations.

Malignant hyperthermia susceptibility-related RYR1 mutations have been described as a common cause of exertional rhabdomyolysis, accounting for up to 30% of presentations in otherwise healthy individuals after exclusion of other causes (22; 49). A predisposing genetic background should be considered if episodes are familial, recurrent, out of context to the exercise performed, or preceded by other symptoms such as cramps, myalgia, and weakness. RYR1-related rhabdomyolysis may occur up to 72 hours after exercise and may mimic viral myositis, and in contrast to other metabolic myopathies, fasting does not appear to be a triggering factor (22; 68).

In a retrospective cohort study including 277 pediatric and adult patients referred for malignant hyperthermia and inherited myopathies, RYR1 mutations were detected in 77 unrelated patients with a detection rate of 28%, and exertional rhabdomyolysis phenotype was prominent in this Dutch series (97).

RYR1-related malignant hyperthermia susceptibility is allelic to central core disease, and some patients with central core disease may also have malignant hyperthermia susceptibility. Exertional rhabdomyolysis and periodic paralysis may present throughout life (22; 54). Late-onset presentations in the adulthood period highlight relevance of the congenital myopathies for adult neuromuscular practice.

In an ENMC workshop on RYR1-related myopathies, the phenotypical spectrum expanded further, particularly in relation to mutations associated with recessive inheritance, and induced or late myopathic manifestations of dominant mutations previously mainly associated with the malignant hyperthermia susceptibility trait (49).

Highlights from this workshop in terms of clinical phenotypes and genotype-phenotype correlations are summarized below:

	A. Early-onset RYR1-related phenotypes
		1. Dominant RYR1 mutations typically present with congenital hypotonia, weakness, and hip dislocation at birth. Motor milestones are delayed; independent ambulation is eventually achieved. Weakness tends to involve hip girdle and quadriceps with sparing of facial and extraocular muscles.
		2. Dominant and recessive RYR1 mutations with a severe neonatal presentation leading to death are described. Fetal akinesia, arthrogryposis, severe weakness, poor feeding, and respiratory failure in the neonatal period can be the initial presentation.
		3. Recessive RYR1 mutations have a tendency of earlier and more severe presentation compared to most patients with dominant mutations; however, they are also associated with a wide range of clinical phenotypes and pathological changes.
		4. RYR1-related centronuclear myopathy (CNM) present with external ophthalmoparesis of variable degree, frequently associated with facial weakness.
		5. Histopathological pattern may resemble congenital fiber type disproportion and congenital muscular dystrophy.
		6. Recessive RYR1-associated phenotypes can be grouped as clinical groups with and without ophthalmoparesis.
		7. Bilateral congenital lumbar hernias in an infant with RYR1-related central core disease.
		8. Gain-of-function RYR1 mutations may lead to prolonged bleeding by altering vascular smooth muscle cell function.
	B. Late-onset RYR1-related phenotypes
		1. Malignant hyperthermia susceptibility 2. King-Denborough syndrome 3. Exertional rhabdomyolysis 4. Periodic paralysis 5. Late-onset axial myopathy
	C. SEPN1-related multiminicore myopathy
		1. Head lag and neck flexor weakness may evolve into rigid spine deformity. Patients with rigid spine deformity and scoliosis should be managed with early respiratory insufficiency and nocturnal hypoventilation. 2. Facial weakness is common but of variable severity, whereas the extraocular muscles are spared. 3. Intelligence is normal. 4. Cardiac involvement is usually in the form of corpulmonale secondary to respiratory insufficiency, rather than primary myocardial involvement. Cardiomyopathy may be more common in late-onset cases.

Bilateral congenital lumbar hernias in an infant with central core disease, severe clinical phenotype, multiple joint contractures, decreased muscle bulk, symptoms of malignant hyperthermia, and RYR1 gene mutation have been described (58). Congenital lumbar hernias are rare malformations caused by defects in the development of posterior abdominal wall. Authors hypothesize that RYR1 mutations may affect posterior wall development by causing inappropriate calcium fluctuations and influencing downstream signaling pathways (58).

Mild bleeding abnormalities are described in patients with malignant hyperthermia carrying gain-of-function RYR1 mutations (61). Knock-in mice with the malignant hyperthermia susceptibility RYR1 mutation Y522S had longer bleeding times than their wild-type littermates, and these mice exhibited higher frequency of subplasmalemmal Ca⁺² sparks, leading to a more negative resting membrane potential. The bleeding defect of mice and one patient was reversed by treatment with RYR1 antagonist dantrolene, and Ca⁺² sparks in primary vascular smooth muscle cells were blocked in the mice model.

Authors conclude that RYR1 mutations may lead to prolonged bleeding by altering vascular smooth muscle cell function, and they emphasize the a) reversible nature of the bleeding phenotype and b) potential therapeutic value of dantrolene in the treatment of bleeding disorders (61).

Multiminicore disease is a clinically heterogeneous disorder. Four major clinical subgroups are recognized (30; 31; 75; 54; 53). Core phenotype due to SEPN1-related myopathies can be defined as predominant axial weakness, early spinal rigidity, scoliosis, and respiratory involvement. There is a disproportion between axial and skeletal muscle weakness. This is the most common (approximately 75% of all cases) “classic” form in the neonatal period or first year of life. A history of reduced fetal movements can be elicited in as many as 30% of cases (52). Affected infants are hypotonic and weak and have delayed motor development. Some children have associated congenital abnormalities such as cleft palate, dislocated hips, or arthrogryposis (30). Physical examination reveals generalized hypotonia, joint hyperlaxity, and asthenic phenotype with decreased muscle bulk. Short stature and failure to thrive are common in children with significant weakness. Intelligence is normal. Weakness in the classic form is predominantly axial. The neck flexors are usually the most affected muscles, with poor or absent head control in infancy being characteristic of this disorder. There is mild to moderate weakness of the proximal limb muscles. Facial weakness is common but of variable severity, whereas the extraocular muscles are spared. The deep tendon reflexes are absent or diminished. There is often a Gowers sign. Extremity weakness may be static or slowly progressive or may even appear to improve slightly with increasing age (80). Progressive weakness of the axial musculature often results in kyphoscoliosis and spinal rigidity of variable severity (30; 99; 15; 75). Paraspinal rigidity and kyphoscoliosis frequently lead to early-restrictive respiratory dysfunction with progressive respiratory insufficiency, which may be rapid in onset. Weakness and spinal deformity are usually static after adolescence. Minor contractures of the elbows, knees, and hips may develop after infancy but are generally not problematic. Because limb weakness is often relatively mild, most patients are ambulant well into adulthood, even in the presence of significant respiratory compromise. Up to two thirds of patients with the classic form of minicore disease develop respiratory insufficiency in late adolescence or early adulthood (30; 31). Cardiac involvement is usually in the form of cor pulmonale secondary to respiratory insufficiency, rather than primary myocardial involvement. About 50% of cases of “classic” multiminicore disease are caused by recessive mutations in the SEPN1 gene (32).

Adult-onset “classic” multiminicore disease is seen in a minority of cases, often in association with the rigid spine syndrome (30), which may be associated with respiratory impairment and development of cor pulmonale (103). Cardiomyopathy may be more common in late-onset cases (95; 64; 78). Occasional cases of adult-onset multiminicore disease presenting with myalgia have been reported (98; 25).

The moderate form of multiminicore disease with hand involvement is relatively rare (fewer than 10% of all cases) and is characterized by relatively mild distal weakness of the upper limbs with hand amyotrophy and marked joint hyperlaxity. The lower extremities are mildly affected with proximal pelvic girdle weakness. Scoliosis and respiratory involvement are minimal or absent (30).

Fewer than 10% of cases of multiminicore disease are of the ophthalmoplegic form, in which there is external ophthalmoplegia in addition to proximal limb weakness (41; 52; 70). This form of minicore disease may be associated with recessive mutations in RYR1 (47).

Less than 10% of all cases present in the neonatal period with arthrogryposis. Affected infants have severe generalized joint contractures as a consequence of markedly decreased movement in utero. Other characteristic findings, also related to decreased fetal motion, include a high-arched palate, low-set ears, short neck, and clinodactyly (30). The genetic basis of this form of multiminicore disease is unknown (47).

There is a huge phenotypic variability in multiminicore disease. Spanish kindreds with a dominantly inherited distal myopathy with weakness of the great toe and ankle dorsiflexors and often associated neck flexor, finger extensor, and mild facial weakness were found to have minicore myopathy caused by the common mutation in the MYH7 (beta-myosin heavy chain protein) gene, which is more commonly known to cause Laing distal myopathy (73). A report described two kindreds with minicore disease caused by dominant mutations in MYH7, presenting in childhood with proximally predominant weakness with progression in adulthood to distal weakness and dilated cardiomyopathy (15).

Recessive mutations of a satellite cell gene (MEGF10) are also implicated in multicore disease (11). Clinical phenotype is characterized by early-onset myopathy, areflexia, respiratory distress, and dysphagia (EAMRDD) (60).

At the beginning of 2020, TRIP4 mutations leading to loss of the coactivator protein ASC1, which direct binds to transcription factors, have been shown to cause multiminicore disease with a contractural phenotype (104).

Table 1. Congenital Myopathy Causing Genes

Gene	CCD	MmD	DuCD	Core-rod
RYR1	+++	+	+	+
SELENON				++
MYH2				+
MYH7				+
TTN				+
CCDC78				+
UNC45B				+
ACTN2				+
MEGF10				+
NEB				+
ACTA1				+
KBTBD13				+
CFL2				+
TRIP4				+
TNNT1				+
Adapted from (39; 76; 77; 18).

Congenital myopathy causing genes

The new genes not previously linked to a congenital myopathy are indicated in bold and underlined. (From: de Feraudy Y, Vandroux M, Romero NB, et al. Exome sequencing in undiagnosed congenital myopathy reveals new genes and ref...

Prognosis and complications

The course is static or slowly progressive in most central core disease patients. Involvement of the respiratory muscles may be of insidious onset and may remain subclinical until unmasked by intercurrent illness or anesthesia. Lung function should be monitored with serial pulmonary function tests, and where indicated, polysomnography. Cardiac complications are uncommon, but baseline electrocardiography and echocardiography are appropriate in most cases of suspected myopathy. Children should be monitored for the development of scoliosis and other skeletal deformities (108).

Many patients with central core disease are at risk of developing malignant hyperthermia during a general anesthetic. As the first exposure to trigger substances elicits an event in only 50% of malignant hyperthermia susceptibility patients, a previous history of tolerance of halogenated anesthetic agents or depolarizing muscle relaxants does not guarantee that these agents can be used safely in future anesthetics. Appropriate anesthetic precautions should be taken in all instances (108).

Nonskeletal muscle presentations of RYR1-related myopathies are described because RyR1 receptors are expressed in a range of other tissues (49). These can be summarized as bleeding abnormalities (61): severe CNS involvement in an adolescent suffering a fatal malignant hyperthermia episode, olanzapine as a triggering agent, with a cerebellar involvement showing similarities to deceased heat stroke victims (34), and evidence of cardiac involvement described in the form of sudden death at a relatively early age by a patient with a late-onset myopathy who died suddenly at the end of running a marathon in the Dutch cohort of patients (49).

Smooth muscle cell involvement in the arteries and arterioles could be an explanation, and these complications and possible CNS and cardiac phenotypes should be investigated in detail.

Minicore myopathy follows a variable course. In many patients, the condition remains benign with static or slowly progressive weakness of the extremities and retention of independent mobility. In some, spinal rigidity becomes a clinically predominant feature in late childhood or adolescence. Severe progressive scoliosis is apparent in a minority. Surgical fixation of the spine is required in most such cases. Minor contractures of the elbows, knees, and hips may develop after infancy and are generally amenable to physiotherapy.

Progressive scoliosis or respiratory insufficiency is seen in up to two thirds of patients with the “classic” form of multiminicore disease, although the ability to walk independently is often preserved even in adults with respiratory failure. There is a marked discrepancy between profound respiratory impairment and preserved ambulation (54). Mortality from multiminicore disease is usually related to complications of respiratory disease. Mortality related to cardiac involvement is uncommon but has occasionally been reported (95; 64; 15). Significant cardiomyopathy in minicore myopathy should prompt consideration of short-chain acyl-CoA dehydrogenase deficiency (100).

Clinical vignette

Case 1. A 10-year-old boy was referred from the pediatric gastroenterology department with a previous diagnosis of celiac disease. He had an asthenic phenotype and growth failure, which was noticed at 2 years of age. Prenatal and natal histories were uneventful. Parents noted that his head control was at 2 years of age, although he was able to walk without support at the age of 14 months. Onset of scoliosis was around the age of 7 years. Parents were first cousins. Family history was negative for a neuromuscular disease.

An asthenic phenotype, decreased muscle bulk, achieving head control later than the ability to walk unsupported, and consanguinity were clues for a neuromuscular disease primarily involving the axial muscles.

Physical examination revealed an asthenic phenotype, decreased muscle bulk, cervical spinal rigidity, mild scoliosis at the thoracic level, neck flexor muscle weakness (MRC 2 of 5), proximal skeletal weakness in upper and lower extremities (MRC 4 of 5), and Gower sign. There was no extraocular involvement and facial weakness.

Patient with SEPN1-related multiminicore disease (MmD) phenotype

A typical 10-year-old patient with SEPN1-related multiminicore disease (MmD) phenotype. Pictures A to D show asthenic, atrophic phenotype, decreased muscle bulk, rigid spine deformity, weakness in neck flexor muscles, and scoliosi...

Asthenic phenotype, rigid spine deformity, and scoliosis necessitate including a neuromuscular disease in the differential diagnosis. Head lag and discrepancy between head control and skeletal muscle weakness were further clues for SEPN1-related myopathies, congenital muscular dystrophy with rigidity of spine (RSMD1), and laminopathies.

Serum creatine kinase level was normal. Muscle biopsy was consistent with minicore myopathy. Molecular genetic analysis revealed a homozygous c.817G-A (p.G273R) mutation in SEPN1. Respiratory function tests (forced vital capacity (FCV): 31% and polysomnography) were consistent with restrictive respiratory dysfunction and nocturnal hypoventilation syndrome. The patient was followed with pediatric chest diseases specialists and remained stable on nocturnal noninvasive ventilatory support (BiPAP).

Biological basis

Etiology and pathogenesis

Central core disease is caused by mutations in the RYR1 gene on chromosome 19q13.1. The RYR1 gene encodes a protein product, the calcium release channel ryanodine receptor (RyR1), which is highly expressed in skeletal muscle sarcoplasmic reticulum, B lymphocytes, and lymphoblastoid cells (40). The skeletal muscle ryanodine RyR1 is a 560 kDa tetrameric structure that, when triggered, allows release of calcium from the lumen of the sarcoplasmic reticulum into the sarcoplasm, triggering muscle contraction. Proteins associated with the RyR1 include the dihydropteridine receptor, FK506 binding protein, calmodulin, triadin, and calsequestrin. Skeletal muscle excitation-coupled calcium entry relies on the interaction between the sarcolemmal 1,4-dihydropyridine receptor and the RyR1 on the sarcoplasmic reticulum membrane. Excitation-coupled calcium entry is strongly enhanced in cells from patients with central core disease compared with individuals with malignant hyperthermia and controls (101).

The RYR1 gene is large (containing 106 exons), rendering genotype-phenotype correlation difficult.

Mutations in the ryanodine gene can be identified in more than 90% of patients with central core disease when all parts of the RYR1 are carefully sequenced (110). Mutations causing central core disease and malignant hyperthermia cluster to three regions of the RYR1 gene. Approximately 50% of patients with clinical evidence of a myopathy and central cores on muscle biopsy have a mutation in region 3 in exons 93 to 104 of RYR1 (72).

The RyR1 controls calcium release during excitation-contraction coupling. In patients with central core disease, RYR1 mutations result in muscle weakness by either causing abnormal “leakiness” of calcium channels, with augmented release of calcium from the sarcoplasmic endoplasmic reticulum (04), or by altering excitation-contraction coupling. Channel “leakiness” appears to be more profound with mutations causing muscle weakness than in those causing only malignant hyperthermia susceptibility (12). Some central core disease-causing RYR1 mutations, however, do not significantly modify calcium release and likely cause muscle weakness by altering excitation-contraction coupling in muscle contraction (82; 05). This hypothesis has been supported by studies showing abnormal distribution of calcium-handling proteins, including those of the sarcoplasmic reticulum (calsequestrin, SERCA1/2, and triadin) and the T-tubule (dihydropyridine receptor-alpha1subunit) in RYR1-associated core myopathies (45). RYR1 mutations associated with both malignant hyperthermia susceptibility and central core disease may cause both calcium depletion from the sarcoplasmic reticulum and increased basal calcium levels, whereas those associated with malignant hyperthermia alone may result in a more modest increase in basal calcium levels without an overall increase in net sarcoplasmic reticulum calcium content (21). Mutations causing dominant central core disease alone tend to result in leaky channels, leading to depletion of calcium from sarcoplasmic reticulum stores. In contrast, mutations causing malignant hyperthermia susceptibility, without central core disease, render the RyR1 hypersensitive to activation by electrical and pharmacological stimuli. A minority of RYR1 mutations is unveiled by silencing of the wild type allele, causing a decrease in expression of mutant RYR1 channels on sarcoplasmic reticulum membrane. Recessive RYR1 mutations may cause a marked decrease in sarcoplasmic reticulum calcium release during excitation-contraction coupling (111; 38). The majority of gene mutations in recessive central core disease are either missense or nonsense mutations (02).

Interestingly, RyR1 are also expressed in the brain, with high levels in the cerebellum, hippocampus, and hypothalamus, where they play a role in voltage-induced calcium release in nerve terminals (17).

Central core disease has traditionally been regarded as an autosomal dominant disease with variable penetrance. De novo mutations are relatively common (72). The new mutation rate is estimated to be about 10%.

Autosomal recessive inheritance of central core disease has been recognized in a number of families (32; 50; 70; 87; 56). Recessive central core disease links to RYR1 but demonstrates more clinical and pathologic heterogeneity than that is seen with dominant inheritance. Protein expression studies variably suggest a correlation between specific mutations, protein levels, and phenotype. Although patients with dominant or recessive mutations associated with typical central core disease phenotypes appear to have normal RyR1 expression, individuals with more generalized weakness, multiminicores, and external ophthalmoplegia have a pronounced depletion of RyR1 expression (114; 02). Recessive core disease may be more common than has previously been recognized. A specific genetic mechanism of recessive core disease may be monoallelic RYR1 transcription, or limitation of RNA transcription from one of the mutated RYR1 alleles, which appears to occur as a tissue-specific phenomenon in some individuals with central core disease. In such cases, the nonexpressed allele is often maternally derived (113).

An ENMC International workshop is dedicated to RYR1-related myopathies; clinical spectrum, genotype-phenotype correlations, basic science, animal models, therapy development, clinical trials, and challenges have been discussed extensively (49).

The pathological hallmark of central core disease is the presence of well-demarcated cores (round or oval shaped regions within a muscle fiber that lack oxidative enzyme activity on histochemical stains) within type 1 muscle fibers. There is usually type 1 fiber predominance, which may be most marked in those with RYR1 mutations at the C-terminal (110). Cores usually extend along most or all of the length of the fiber. There may be one or more cores within a fiber. Although the biopsy may show other myopathic features such as fiber size variability, increased internal nuclei, and fiber splitting, the presence of cores as the predominant pathological feature in the biopsy establishes the diagnosis of central core disease. Necrosis and significant fiber regeneration are uncommon, but extensive fibrosis and fatty infiltration are seen occasionally (94).

Cores may be centrally or eccentrically placed and, in a minority of cases, may resemble minicores, raising the possibility of the separate but related disorder minicore myopathy, which is generally autosomal recessive in inheritance. In such cases, microscopic evaluation of cross sections may not distinguish between central core disease and multiminicore disease, whereas longitudinal sections reveal the cores of central core disease to run the whole length of the fiber. Those of multiminicore disease are usually shorter and are seen in both type 1 and type 2 fibers. Diagnosis is also difficult in the small number of patients whose muscle biopsy demonstrates uniformity of type 1 fibers without cores. This entity, now known as congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation (CNMDU1), is caused by mutations in RYR1 in 40% of cases (90). Cores and nemaline rods are seen in tandem in some kindreds with dominant RYR1 mutations (71; 91; 46).

Desmin (an intermediate filament protein found in muscle fibers) reactivity, detected by an indirect immunofluorescence assay, is abnormal in cores (102). Accumulations of desmin are seen in many other myopathies. Myotilin, a Z-disc protein that binds alpha-actinin, gamma-filamin, and F-actin, is also present in central cores (92). Immunocytochemistry is helpful in demonstrating cores but shows no other specific abnormalities in central core disease (94).

Electron microscopic examination of cores shows an absence of mitochondria, the anatomical correlate to the loss of oxidative enzyme activity in histochemical reactions. The appearance of the myofibrillar contractile apparatus is variable in the cores; it ranges from essentially normal (structured) to significantly disrupted (unstructured) (74).

There is no clear correlation between biopsy findings and clinical phenotype in central core disease (02).

In an ENMC workshop, a summary of the main pathological features of muscle biopsies from patients with RYR1 mutations are presented, with an emphasis on heterogeneity of pathology and limitations in our understanding of their meaning (49). In some young cases, increase in adipose and connective tissue can be extensive resembling congenital muscular dystrophies. Of note, sampling may be a factor because of differential involvement of muscles, there may be evolution of biopsy findings, and patients presenting with exertional myalgia and malignant hyperthermia often show mild, nonspecific myopathic pathological features (49).

Muscle MRI may help to define distinct pattern of involvement and can be used as a potential biomarker for disease severity in neuromuscular conditions (47; 109).

Selenoprotein N, a glycoprotein, localizes to the endoplasmic reticulum and is found at low levels in virtually all body tissues. Other selenoproteins are involved in reduction-oxidation process or processing of thyroid hormone. SEPN1 has a calcium binding motif similar to that seen in calmodulin, suggesting a possible role in calcium homeostasis (69), although SEPN1 mutations have not been associated with abnormal localization of calcium-related proteins in or around minicores (45). Selenoprotein N mutations have also been implicated in myogenesis, with work suggesting a possible role in muscle sarcomeric organization and myofiber attachment (20; 59). SEPN1 mutations cause 40% to 50% of cases of classic minicore myopathy (32a).

Mutations in two genes are responsible for approximately 50% of cases of minicore disease. In a study from Italy, mutations of SEPN1 represented 6% of congenital muscular dystrophy patients (42). The proportion related to MYH7 mutations is not known but likely to be low given that dominantly inherited minicore myopathy is uncommon (73; 15; 14).

Recessive mutations in the gene for SEPN1 account for 30% of all multiminicore disease and represent 40% to 50% of all “classic” form (32). Until recently, all identified mutations have been located in the 5’ UTR and coding sequence of SEPN1, consisting of microdeletions or insertions leading to frameshift, splice site mutations causing aberrant RNA splicing, or single nucleotide changes causing missense mutations. A novel mutation in the 3’UTR region of the gene has been reported. This mutation in the selenocysteine insertion sequence of selenoprotein messenger RNA alters binding of a crucial binding protein (SBP2) and decreases SEPN production (01). Most identified mutations result in premature termination of translation; the 5’ remainder representing missense amino acid substitutions. Homozygous mutations of the same gene were originally described in congenital muscular dystrophy with rigid spine (rigid spine muscular dystrophy) (69), an entity that is now felt to represent severe “classic” minicore myopathy presenting in early childhood (32a).

SEPN1 mutations have also been shown to cause desmin-related myopathy with Mallory body-like inclusions, a congenital myopathy characterized by intrasarcoplasmic desmin aggregates (29).

Minicore myopathy is described in subjects with mutations in MYH7, a gene for beta-myosin heavy chain protein usually associated with Laing distal myopathy (73; 15; 14). Weakness in such cases may be of childhood or adult onset, may be proximally or distally predominant, and may be associated with an adult-onset cardiomyopathy.

Recessive RYR1 mutations associated with minicore disease appear to be distributed throughout the RYR1 gene, resulting in abnormalities of excitation-contraction coupling and calcium homeostasis in skeletal muscle (27; 113). RYR1 mutations have been shown to be associated with depletion of ryanodine channels in minicores, with local accumulation of other proteins of the sarcoplasmic reticulum (calsequestrin, SERCA1/2, and triadin) and the T-tubule (dihydropyridine receptor-alpha1subunit) (45). RYR1 mutations have been linked to the moderate form of minicore disease with hand involvement (32b; 50), in a single patient, to the classic form of minicore myopathy (70), and to a tendency to malignant hyperthermia syndrome with pathological (but not clinical) changes consistent with minicore disease (44).

The MYH7 gene encodes slow/beta cardiac myosin heavy chain, a myosin isoform found in cardiac and type I skeletal muscle fibers. Mutations in MYH7 are an established cause of hypertrophic cardiomyopathy and less commonly cause dilated cardiomyopathy and left ventricular noncompaction. MYH7 gene mutations have been linked to a number of skeletal myopathies, including Laing distal myopathy, myosin storage myopathy, congenital fiber-type disproportion, and now minicore myopathy (15; 14).

Recessive mutations of a satellite cell gene (MEGF10) are also implicated in multicore disease (11). Patients present with early-onset myopathy, areflexia, respiratory distress, and dysphagia (EAMRDD) (60).

With a new era in the genetics of neuromuscular diseases and an availability of NGS technologies, being cost-effective and available, a new terminology “diagnosis by sequencing” has been introduced (83). The latest European Malignant Hyperthermia Group diagnostic guidelines have introduced the option of primary DNA screening for the index case. During an ENMC workshop, in a United Kingdom cohort of 126 unrelated patients, RYR1 variants were found in 72 samples, but only 20 of these were the variants known to be pathogenic or likely to be pathogenic, and 16 variants were known polymorphisms or unlikely to be pathogenic, whereas 50% of the RYR1 variants found were of unknown significance (49).

Importance of in depth analysis correlating genotypes with phenotypes, histotypes, and pathophysiological consequences-physiotype is addressed to understand complex relationships (49; 53).

Diagnostic workup

The traditional approach to diagnosing a congenital myopathy is combining detailed clinical and family history with physical examination findings to recognize clues to clarify a phenotype. The International Standard of Care Committee for Congenital Myopathies provides a diagnostic approach and highlights the fact that other than muscle biopsy, investigations are rarely specific for congenital myopathies but are widely used to exclude other possible diagnoses (75).

Evaluation of muscle biopsy is important; however, one should also keep in mind the overlap and morphological abnormalities seen in these conditions, marked variability in their clinical progression, and severity (84).

Serum creatine kinase is usually normal or mildly elevated.

Electromyography (EMG) and nerve conduction studies (NCS) are useful to exclude denervation disorders. EMG is typically normal or shows myopathic features, with short-duration, small-amplitude, polyphasic motor unit potentials.

Muscle imaging (ultrasonography and MRI) may be useful in diagnosis demonstrating a characteristic pattern of selective muscle involvement, which may be used in conjunction with clinical features to guide genetic testing (47; 75).

Relative sparing of the rectus femoris, with increased echogenicity (ie, atrophy) of the vastus intermedius, has been suggested to be characteristic of minicore myopathy (52). Muscle MRI in RYR1-related myopathies has shown involvement of the vasti with selective sparing of the rectus femoris in the thigh, and involvement of soleus and the gastrocnemii below the knee (47b). These findings are similar but more severe in minicore disease in association with ophthalmoplegia (47a), whereas minicore disease associated with SEPN1 mutations is associated with more significant involvement of the gastrocnemii than the soleus, and with selective involvement of the sartorius in the thigh (66).

Muscle biopsy and analysis of muscle histology, histochemistry, immunohistochemistry, and ultrastructure by light and electron microscopy (EM) have been the mainstay of reaching the diagnosis of a specific form of congenital myopathies (75).

There are now a few laboratories worldwide offering diagnostic mutational screening, and the paradigm is shifting from invasive procedures to the new era of next-generation strategies (83). The cost-effectiveness and increasing availability of these techniques in different centers give the opportunity to perform molecular analysis directly.

We believe that investigations at the moment should be complementary to understanding the underlying complex pathomechanisms.

Diagnostic work-up finally includes molecular genetic testing. In a patient with a phenotype consistent with core myopathy, the first RYR1 mutations, mini core myopathy's first SEPN1 mutations, and second RYR1 mutations should be screened (75). In case of associated cardiomyopathy, MYH7 and TTN analysis is recommended (75).

Whole-exome and whole-genome sequencing approaches, wherever available, may help diagnose cost-effectively (83).

Management

Consensus statements on standard of care for congenital myopathies should be considered (108; 24).

The management of congenital myopathies has shown some progress in recent years. Potential therapeutic approaches for congenital myopathies can be divided into the following aspects: treatment of potential genetic defects, calcium/myosin regulation targeting muscle contraction, and therapies that target genes involved in a pathway (112).

Core elements of treatment include physical therapy, orthopedic interventions, management of respiratory complications, and feeding problems.

There are currently no approved treatments for the possible genetic defects in congenital myopathy. The management of the congenital myopathies is currently supportive and based on a multidisciplinary team approach involving a neuromuscular neurologist, respiratory physicians, orthopedic surgeons, physiotherapists, occupational therapists, and speech-language therapists (105) The primary focus is on managing associated symptoms, particularly respiratory dysfunction that can be latent and life-threatening, often ranging from noninvasive ventilation during nocturnal sleep to almost permanent mechanical ventilation via tracheostomy (112).

Involvement of the respiratory muscles may have an insidious onset and may remain subclinical until unmasked by intercurrent illness or anesthesia. Respiratory function should be monitored with serial pulmonary function tests, and where indicated, sleep studies.

Many patients have difficulty chewing and swallowing and require a gastrostomy for feeding. Tube feeding is necessary for infants and young children with poor sucking ability.

Patients with congenital myopathy and skeletal deformities such as clubfoot, pectus excavatum, scoliosis, and short ribs may require surgical correction or conservative treatment based on their condition.

Children should be monitored for the development of scoliosis and other skeletal deformities. Scoliosis may develop quickly and may be of a severity disproportionate to that of limb weakness. Congenital dislocation and dysplasia of the hip require orthopedic treatment. Gamble and colleagues reported a higher number of treatment failures and hip contractures after surgery in children with central core disease than in other myopathies (37).

Cardiac complications are uncommon in central core disease, but baseline electrocardiography and echocardiography are appropriate in most cases (96; 49).

Because malignant hyperthermia susceptibility is common in central core disease, malignant hyperthermia susceptibility should be considered in cases of RYR1, CACNA1S, and STAC3 mutations and in all cases of unknown genetic origin (105). All patients subjected to general anesthesia require preoperative anesthetic consultation and planning to ensure that a nontriggering anesthetic technique is used.

Treatment of malignant hyperthermia, which is a medical emergency, requires dantrolene and additional supportive care measures. Malignant hyperthermia susceptibility is suspected in an individual with congenital myopathy when (a) there is a positive family history of malignant hyperthermia susceptibility, (b) there have been previous difficulties with anesthesia, and (c) the patient has a documented RYR1 mutation (108). Of note, prophylactic dantrolene is not recommended prior to anesthesia, even in cases where malignant hyperthermia susceptibility has been established (108).

An ENMC workshop discusses current and future therapeutic approaches (49; 51). Possible therapeutic strategies include modifying RyR1 function, correcting associated oxidative abnormalities, using a pharmacological compound to enhance muscle contractility or neuromuscular transmission, and correcting a specific gene defect.

A range of more specific therapies are in development or have already reached the clinical trial stage, including antioxidants such as N-acetylcysteine (NAC). These treat the oxidative abnormalities documented in SELENON- and RYR1-associated myopathies, although their effects in clinical trials have been limited. There have also been reports of neuromuscular transmission defects associated with the response of some congenital myopathies to acetylcholinesterase inhibitors or other pharmacological agents used to treat myasthenic diseases (53; 105).

Current and future therapeutic approaches are discussed in an ENMC workshop (49; 51). Modification of RyR1 function, correction of associated oxidative abnormalities, use of pharmacological compound enhancing muscle contractility or neuromuscular transmission, and correction of specific gene defect are discussed in detail as possible therapeutic strategies. N-acetylcysteine (NAC), as an antioxidant for potential treatment for RYR1- and SEPN1-related myopathies, have prompted the first clinical trials in humans currently underway (51).

Individuals with multiminicore disease are usually able to care for themselves in all activities of daily life. Schooling is unaffected. A regime of physical therapy wherein muscle strength is maintained and range of motion preserved is generally appropriate. Minor contractures of the elbows, knees, and hips may develop after infancy and may respond to physical therapy or splinting. Surgical release is rarely necessary.

One study examined the effect of salbutamol, a beta-2 agonist, on effect on muscle strength in central core and minicore disease. Five children with minicore myopathy (average age 13.6 years) received 2 mg salbutamol orally four times a day for 6 months. One stopped the medication because of tremors and palpitations. The other four completed 6 months of therapy, at the end of which, they reported improved stamina and had a small but significant improvement in strength measured by myometry and MRC scores, and in their vital capacity, relative to baseline (67).

The two major complications of multiminicore disease are the development of progressive kyphoscoliosis and progressive deterioration of respiratory function. Monitoring of spinal growth is important, especially during growth spurts. Given the possibility of "malignant" kyphoscoliosis, it is advisable to obtain a surgical opinion as soon as kyphoscoliosis becomes evident, and early spinal operation should be considered in those with progressive respiratory involvement (81). The possible predisposition to malignant hyperthermia should be kept in mind in all patients with multiminicore disease (36).

Respiratory function should be monitored in all affected children, but especially those with significant scoliosis and spinal rigidity (88). The degree of respiratory insufficiency seen in minicore disease is often disproportionate both to the extent of peripheral weakness and to the severity of scoliosis, and in those with significantly diminished reserve, there is potential for life-threatening decompensation of respiratory function with intercurrent illness. Hypoventilation is usually first apparent at night. Prior to the onset of overt diurnal respiratory difficulties, hypoventilation may present with excessive daytime somnolence, early morning headaches, anorexia, and deteriorating school performance. Clues on physical examination include excessive use of accessory muscles and fixed deformities of the thoracic cage. Symptoms and signs of chronic hypoventilation may be difficult to ascertain or even lacking in affected children; however, all patients should undergo regular (annual or more frequent) formal assessment of respiratory function. This should include lung function tests specifically assessing the forced vital capacity, forced expired volume in 1 second, maximal inspiratory and expiratory pressures, and the cough peak flow (65). Significant falls in the vital capacity when measured supine, as opposed to sitting or standing, infer diaphragmatic dysfunction and identify patients with diminished respiratory reserve.

Polysomnographic evaluation should also be undertaken in order to evaluate for subclinical nocturnal hypoventilation. Patients with severe scoliosis often require ventilatory support, the first line of which is usually nocturnal assisted ventilation followed if necessary by daytime noninvasive positive pressure ventilation. Nocturnal ventilatory support may both prolong life and improve quality of life in children with chronic neuromuscular respiratory insufficiency (107).

Evaluation of cardiac function, in the form of a clinical assessment, ECG, and echocardiogram, should be undertaken at baseline and in patients with progressive skeletal weakness or respiratory insufficiency. Cardiac involvement in multiminicore disease is most commonly in the form of cor pulmonale as a sequela of progressive respiratory failure, but occasional cases have been associated with primary cardiomyopathy (64; 09; 88).

Genetic counseling should be provided to all affected families.

There are ongoing efforts to try oral dantrolene in RYR1-related myopathies. We should learn more in the future.

Special considerations

Pregnancy

The congenital myopathies carry a slightly increased risk of breech and other abnormal presentations (62; 28). Specific complications of pregnancy in patients with central core disease have not been reported.

Precautions like those for other patients with muscle weakness apply to patients with minicore myopathy. Loss of respiratory reserve in advanced pregnancy may be of concern in those with significant pulmonary disease. Successful pregnancies have been reported in families with dominant inheritance. In these families, affected offspring have been symptomatic from birth (95). Successful delivery using epidural anesthesia has been reported in malignant hyperthermia-susceptible patients with multiminicore disease (89).

Anesthesia

Malignant hyperthermia susceptibility is a common accompaniment of central core disease; all patients with central core disease who are to be subjected to a general anesthetic and whose susceptibility to malignant hyperthermia is unknown require preoperative anesthetic consultation and planning to ensure that a nontriggering anesthetic technique is used. A review discusses appropriate evaluation and anesthetic management in patients with core myopathies (13).

Of 297 unrelated malignant hyperthermia patients studied in the United Kingdom, 85 were shown to have RYR1 mutations; 10 patients also had central core disease (86). A similar study of 124 unrelated North American malignant hyperthermia patients identified RYR1 mutations in 29 cases (23%) (93).

Although not routinely performed, definitive diagnostic test for malignant hyperthermia involves an in vitro contracture test, which is based on increased sensitivity to stimuli usually inducing calcium release by the sarcoplasmic reticulum. The degree of muscle contraction after exposure to halothane and caffeine is a specific and sensitive marker of malignant hyperthermia susceptibility. The in vitro contracture test requires a fresh muscle biopsy and is not well standardized in children.

In a 25-year retrospective study from the Hospital for Sick Children, Canada; 13 patients were identified with malignant hyperthermia-like reactions (06). Nine patients were classified as having true malignant hyperthermia after review of anesthesia record, and genetic testing results were available for seven patients, five of whom had mutations in RYR1. Of the four patients who had severe reactions to anesthesia but did not meet the criteria for true malignant hyperthermia, two had Duchenne muscular dystrophy (06).

Limitations are those that apply to all myopathies wherein respiratory function may be reduced. At least a single death has occurred following an anesthetic (55). In common with central core disease, malignant hyperthermia has been reported in patients with multiminicore disease, so anesthetics should be given with caution (36; 79; 89). Formal testing for a predisposition to malignant hyperthermia should be considered prior to elective anesthesia.

Advanced kyphoscoliosis may pose a particular problem in anesthesia because of distortion of the thoracic cage.

References

01: Allamand V, Richard P, Lescure A, et al. A single homozygous point mutation in a 3'untranslated region motif of selenoprotein N mRNA causes SEPN1-related myopathy. EMBO Rep 2006;7(4):450-4. PMID 16498447
02: Amburgey K, Bailey A, Hwang JH, et al. Genotype-phenotype correlations in recessive RYR1-related myopathies. Orphanet J Rare Dis 2013;8:117. PMID 23919265
03: Amburgey K, McNamara N, Bennett LR, et al. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol 2011;70(4):662-5. PMID 22028225
04: Avila G. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved. Cell Calcium 2005;37(2):121-7. PMID 15589992
05: Avila G, O'Brien JJ, Dirksen RT. Excitation--contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc Natl Acad Sci U S A 2001;98(7):4215-20. PMID 11274444
06: Bamaga AK, Riazi S, Amburgey K, et al. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: a 25-year retrospective study. Neuromuscul Disord 2016;26(3):201-6. PMID 26951757
07: Banker BQ. The congenital myopathies. In: Engel AG, Banker BQ, editors. Myology. Vol 2. New York: McGraw-Hill, 1986:1527-81.
08: Benarroch L, Bonne G, Rivier F, Hamroun D. The 2024 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord 2024;34:126-70. PMID 38253411
09: Bertini E, Bosman C, Bevilacqua M, et al. Cardiomyopathy and multicore myopathy with accumulation of intermediate filaments. Eur J Pediatr 1990;149(12):856-8. PMID 2226571
10: Bharucha-Goebel DX, Santi M, Medne L, et al. Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum. Neurology 2013;80(17):1584-9. PMID 23553484
11: Boyden SE, Mahoney LJ, Kawahara G. Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores. Neurogenetics 2012;13(2):115-24. PMID 22371254
12: Brini M, Manni S, Pierobon N, et al. Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations. J Biol Chem 2005;280(15):15380-9. PMID 15689621
13: Brislin RP, Theroux MC. Core myopathies and malignant hyperthermia susceptibility: a review. Paediatr Anaesth 2013;23(9):834-41. PMID 23617272
14: Clarke NF, Amburgey K, Teener J, et al. A novel mutation expands the genetic and clinical spectrum of MYH-7 related myopathies. Neuromuscul Disord 2013;23(5):432-6. PMID 23478172
15: Cullup T, Lamont PJ, Cirak S, et al. Mutations in MYH7 cause multi-minicore disease (MmD) with variable cardiac involvement. Neuromuscul Disord 2012;22(12):1096-104. PMID 22784669
16: D'Arcy CE, Bjorksten A, Yiu EM, et al. King-Denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008;71(10):776-7. PMID 18765655
17: De Crescenzo V, Fogarty KE, Lefkowitz JJ, et al. Type 1 ryanodine receptor knock-in mutation causing central core disease of skeletal muscle also displays a neuronal phenotype. Proc Natl Acad Sci U S A 2012;109(2):610-5. PMID 22203976
18: de Feraudy Y, Vandroux M, Romero NB, et al. Exome sequencing in undiagnosed congenital myopathy reveals new genes and refines genes–phenotypes correlations. Genome Med 2024;16(1):87. PMID 38982518
19: Denborough MA, Dennett X, Anderson RM. Central-core disease and malignant hyperpyrexia. Br Med J 1973;1:272-3. PMID 4265427
20: Deniziak M, Thisse C, Rederstorff M, Hindelang C, Thisse B, Lescure A. Loss of selenoprotein N function causes disruption of muscle architecture in the zebrafish embryo. Exp Cell Res 2007;313(1):156-67. PMID 17123513
21: Dirksen RT, Avila G. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 2004;87(5):3193-204. PMID 15347586
22: Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013;23(7):540-8. PMID 23628358
23: Dowling JJ, Lillis S, Amburgey K, et al. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2011;21(6):420-7. PMID 21514828
24: Dowling JJ, North KN, Goebel HH, Beggs AH. Congenital and other structural myopathies. In: Darras BT, Jones R Jr, Ryan MM, De Vivo Darryl DC. Neuromuscular disorders of infancy, childhood, and adolescence. A Clinician’s Approach. Second edition. London :Elsevier, 2014.
25: Duarte ST, Oliveira J, Santos R, et al. Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms. Muscle Nerve 2011;44(1):102-8. PMID 21674524
26: Dubowitz V, Pearse AG. Oxidative enzymes and phosphorylase in central-core disease of muscle. Lancet 1960;2(7140):23-4. PMID 13818365
27: Ducreux S, Zorzato F, Ferreiro A, et al. Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes. Biochem J 2006;395(2):259-66. PMID 16372898
28: Engel AG, Gomez MR, Groover RV. Multicore disease. A recently recognized congenital myopathy associated with multifocal degeneration of muscle fibers. Mayo Clin Proc 1971;46(10):666-81. PMID 5115748
29: Ferreiro A, Ceuterick-de Groote C, Marks JJ, et al. Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene. Ann Neurol 2004;55(5):676-86. PMID 15122708
30: Ferreiro A, Estournet B, Chateau D, et al. Multi-minicore disease--searching for boundaries: phenotype analysis of 38 cases. Ann Neurol 2000;48(5):745-57. PMID 11079538
31: Ferreiro A, Fardeau M. 80th ENMC International Workshop on multi-minicore disease: 1st International MmD Workshop. 12-13th May, 2000, Soestduinen, The Netherlands. Neuromusc Disord 2002;12(1):60-8. PMID 11731287
32: Ferreiro A, Monnier N, Romero NB, et al. A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Ann Neurol 2002;51:750-9. PMID 12112081
33: Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002a;71(4):739-49. PMID 12192640
34: Forrest KM, Foulds N, Millar JS, et al. RYR1-related malignant hyperthermia with marked cerebellar involvement- a paradigm of heat-induced CNS injury? Neuromuscul Disord 2015;25(2):138-40. PMID 25466363
35: Frank JP, Harati Y, Butler IJ, Nelson TE, Scott CI. Central core disease and malignant hyperthermia syndrome. Ann Neurol 1980;7:11-7. PMID 7362206
36: Galli L, Orrico A, Cozzolino S, Pietrini V, Tegazzin V, Sorrentino V. Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: evidence for a cluster of novel mutations in the C-terminal region. Cell Calcium 2002;32:143-51. PMID 12208234
37: Gamble JG, Rinsky LA, Lee JH. Orthopedic aspects of central core disease. J Bone Joint Surg 1988;70:1061-6. PMID 3403575
38: Ghassemi F, Vukcevic M, Xu L, et al. A recessive ryanodine receptor 1 mutation in a CCD patient increases channel activity. Cell Calcium 2009;45(2):192-7. PMID 19027160
39: Gineste C, Laporte J. Therapeutic approaches in different congenital myopathies. Curr Opin Pharmacol 2023;68:102328. PMID 36512981
40: Girard T, Cavagna D, Padovan E, et al. B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001;276:48077-82. PMID 11673462
41: Gordon PH, Hays AP, Rowland LP, et al. Erroneous diagnosis corrected after 28 years: not spinal muscular atrophy with ophthalmoplegia but minicore myopathy. Arch Neurol 1996;53(11):1194-6. PMID 8912497
42: Graziano A, Bianco F, D’Amico A, et al. Prevalence of congenital muscular dystrophy in Italy: a population study. Neurology 2015;84(9):904-11. PMID 25653289
43: Greenfield JG, Cornman T, Shy GM. The prognostic value of the muscle biopsy in the floppy infant. Brain 1958;81:461-84. PMID 13618447
44: Guis S, Figarella-Branger D, Monnier N, et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004;61(1):106-13. PMID 14732627
45: Herasse M, Parain K, Marty I, et al. Abnormal distribution of calcium-handling proteins: a novel distinctive marker in core myopathies. J Neuropathol Exp Neurol 2007;66(1):57-65. PMID 17204937
46: Hernandez-Lain A, Husson I, Monnier N, et al. de novo RYR1 heterozygous mutation (I4898T) causing lethal core-rod myopathy in twins. Eur J Med Genet 2011;54(1):29-33. PMID 20888934
47: Jungbluth H, Beggs A, Bonnemann C, et al. 111th ENMC International Workshop on Multi-minicore Disease. 2nd International MmD Workshop, 9-11 November 2002, Naarden, The Netherlands. Neuromuscul Disord 2004a;14(11):754-66. PMID 15482962
48: Jungbluth H, Davis MR, Muller C, et al. Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations. Neuromuscul Disord 2004b;14(12):785-90. PMID 15564033
49: Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F, RYR1 Myopathy Consortium. 217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29-31 January 2016. Neuromuscul Disord 2016;26(9):624-33. PMID 27377473
50: Jungbluth H, Muller CR, Halliger-Keller B, et al. Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 2002;59:284-7. PMID 12136074
51: Jungbluth H, Ochala J, Treves S, Gautel M. Current and future approaches to the congenital myopathies. Semin Cell Dev Biol 2017;64:191-200. PMID 27515125
52: Jungbluth H, Sewry C, Brown SC, et al. Minicore myopathy in children: a clinical and histopathological study of 19 cases. Neuromusc Disord 2000;10(4-5):264-73. PMID 10838253
53: Jungbluth H, Treves S, Zorzato F, et al. Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction. Nat Rev Neurol 2018;14(3):151-67. PMID 29391587
54: Jungbluth H, Voermans NC. Congenital myopathies: not only a paediatric topic. Curr Opin Neurol 2016;29(5):642-50. PMID 27538056
55: Koch BM, Bertonrini TE, Eng GD, Boehm R. Severe multicore disease associated with reaction to anesthesia. Arch Neurol 1985;42:1204-6. PMID 4062619
56: Kossugue PM, Paim JF, Navarro MM, et al. Central core disease due to recessive mutations in RYR1 gene: is it more common than described. Muscle Nerve 2007;35(5):670-4. PMID 17226826
57: Krisovic-Horber R, Krisovic I. Central core disease associated with malignant hyperthermia sensitivity. Presse Med 1989;18(16):828-31. PMID 2524766
58: Lazier J, Mah JK, Nikolic A, et al. Bilateral congenital lumbar hernias in a patient with central core disease—A case report. Neuromuscul Disord 2016;26(1):56-9. PMID 26684984
59: Lescure A, Deniziak M, Rederstorff M, Krol A. Molecular basis for the role of selenium in muscle development and function. Chem Biodivers 2008;5(3):408-13. PMID 18357550
60: Logan CV, Lucke B, Pottinger C, et al. Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD). Nat Genet 2011;43(12):1189-92. PMID 22101682
61: Lopez RJ, Byrne S, Vukcevic M, et al. An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding abnormalities. Sci Signal 2016;9(435):ra68. PMID 27382027
62: Magee KR, Shy GM. A new congenital non-progressive myopathy. Brain 1956;79(4):610-21. PMID 13396066
63: Maggi L, Scoto M, Cirak S, et al. Congenital myopathies--clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscul Disord 2013;23(3):195-205. PMID 23394784
64: Magliocco AM, Mitchell LB, Brownell AK, Lester WM. Dilated cardiomyopathy in multicore myopathy. Am J Cardiol 1989;63(1):150-1. PMID 2909155
65: Mellies U, Ragette R, Schwake C, Boehm H, Voit T, Teschler H. Daytime predictors of sleep disordered breathing in children and adolescents with neuromuscular disorders. Neuromusc Disord 2003;13(2):123-8. PMID 12565909
66: Mercuri E, Talim B, Moghadaszadeh B, et al. Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1). Neuromuscul Disord 2002;12(7-8):631-8. PMID 12207930
67: Messina S, Hartley L, Main M, et al. Pilot trial of salbutamol in central core and multi-minicore diseases. Neuropediatrics 2004;35(5):262-6. PMID 15534757
68: Molenaar JP, Voermans NC, van Hoeve BJ, et al. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Intern Med J 2014;44(8):819-20. PMID 25081049
69: Moghadaszadeh B, Petit N, Jaillard C, et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet 2001;29(1):17-8. PMID 11528383
70: Monnier N, Ferreiro A, Marty I, Labarre-Vila A, Mezin P, Lunardi J. A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. Hum Mol Genet 2003;12(10):1171-8. PMID 12719381
71: Monnier N, Romero NB, Lerale J, et al. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum Mol Genet 2000;9(18):2599-608. PMID 11063719
72: Monnier N, Romero NB, Lerale J, et al. Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Genet 2001;10(22):2581-92. PMID 11709545
73: Muelas N, Hackman P, Luque H, et al. MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy. Neurology 2010;75(8):732-41. PMID 20733148
74: Neville HE. Ultrastructural changes in muscle disease. In: Dubowitz V, Brooke MH. Muscle biopsy: a modern approach. London: Saunders, 1973:383-470.
75: North KN, Wang CH, Clarke N, et al. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord 2014;24(2):97-116. PMID 24456932
76: Ogasawara M, Nishino I. A review of core myopathy: central core disease, multiminicore disease, dusty core disease, and core-rod myopathy. Neuromuscul Disord 2021;31(10):968-77. PMID 34627702
77: Ogasawara M, Nishino I. Update on RYR1-related myopathies. Curr Opin Neurol 2024;37(5):504-8. PMID 38994695
78: Ohkubo M, Ino T, Shimazaki S, Yabuto K, Okada R, Sato T. Multicore myopathy associated with multiple pterygium syndrome and hypertrophic cardiomyopathy. Pediatr Cardiol 1996;17(1):53-6. PMID 8778704
79: Osada H, Masuda K, Seki K, Sekiya S. Multi-minicore disease with susceptibility to malignant hyperthermia in pregnancy. Gynecol Obstet Invest 2004;58(1):32-5. PMID 15056993
80: Panegyres PK, Kakulas BA. The natural history of minicore-multicore myopathy. Muscle Nerve 1991;14(5):411-5. PMID 1831245
81: Pellengahr C, Krodel A, Muller-Hocker J, Pongratz D. Rapidly progredient scoliosis associated with multicore disease. Arch Orthop Trauma Surg 1998;117(6-7):411-4. PMID 9709867
82: Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993;5(1):51-5. PMID 8220423
83: Ravenscroft G, Davis MR, Lamont P, Forrest A, Laing NG. New era in genetics of early-onset muscle disease: breakthroughs and challenges. Sem Cell Dev Biol 2017;64:160-70. PMID 27519468
84: Ravenscroft G, Laing NG, Bonnemann CG. Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus. Brain 2015;138(Pt 2):219-27. PMID 25552303
85: Reed UC, Resende MB, Ferreira LG, et al. King-Denborough Syndrome: report of two Brazilian cases. Arq Neuropsiquiatr 2002;60:739-741. PMID 12364941
86: Robinson RL, Brooks C, Brown SL, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 2002;20(2):88-97. PMID 12124989
87: Romero NB, Monnier N, Viollet L, et al. Dominant and recessive central core disease associated with RYR1 mutations and fetal akinesia. Brain 2003;126(Pt 11):2341-9. PMID 12937085
88: Rowe PW, Eagle M, Pollitt C, Bullock RE, Bushby KM. Multicore myopathy: respiratory failure and paraspinal muscle contractures are important complications. Dev Med Child Neurol 2000;42(5):340-3. PMID 10855655
89: Saito O, Yamamoto T, Mizuno Y. Epidural anesthetic management using ropivacaine in a parturient with multi-minicore disease and susceptibility to malignant hyperthermia. J Anesth 2007;21(1):113. PMID 17285432
90: Sato I, Wu S, Ibarra MC, et al. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology 2008;70(2):114-22. PMID 17538032
91: Scacheri PC, Hoffman EP, Fratkin JD, et al. A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy. Neurology 2000;55:1689-96. PMID 11113224
92: Schroder R, Reimann J, Salmikangas P, et al. Beyond LGMD1A: myotilin is a component of central core lesions and nemaline rods. Neuromuscul Disord 2003;13(6):451-5. PMID 12899871
93: Sei Y, Sambuughin NN, Davis EJ, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101(4):824-30. PMID 15448513
94: Sewry CA, Muller C, Davis M, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002;12:930-8. PMID 12467748
95: Shuaib A, Martin JM, Mitchell LB, Brownell AK. Multicore myopathy: not always a benign entity. Can J Neurol Sci 1988;15(1):10-4. PMID 3345455
96: Shuaib A, Paasuke RT, Brownell AK. Central core disease. Clinical features in 13 patients. Medicine 1987;66:389-96. PMID 3626847
97: Snoeck M, van Engelen BG, Kusters B, et al. RYR1-related myopathies: a wide spectrum of phenotypes throughout life. Eur J Neurol 2015;22(7):1094-112. PMID 25960145
98: Sobreira C, Marques W Jr, Barreira AA. Myalgia as the revealing symptom of multicore disease and fibre type disproportion myopathy. J Neurol Neurosurg Psychiatry 2003;74(9):1317-9. PMID 12933945
99: Tajsharghi H, Darin N, Tulinius M, Oldfors A. Early onset myopathy with a novel mutation in the Selenoprotein N gene (SEPN1). Neuromuscul Disord 2005;15(4):299-302. PMID 15792869
100: Tein I, Elpeleg O, Ben-Zeev B, et al. Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. Mol Genet Metab 2008;93(2):179-89. PMID 18054510
101: Treves S, Vukcevic M, Jeannet PY, et al. Enhanced excitation-coupled Ca(2+) entry induces nuclear translocation of NFAT and contributes to IL-6 release from myotubes from patients with central core disease. Hum Mol Genet 2011;20(3):589-600. PMID 21088110
102: van der Ven PF, Jap PH, ter Laak HJ, et al. Immunophenotyping of congenital myopathies: disorganization of sarcomeric, cytoskeletal and extracellular matrix proteins. J Neurol Sci 1995;129(2):199-213. PMID 7608737
103: Venance SL, Koopman WJ, Miskie BA, Hegele RA, Hahn AF. Rigid spine muscular dystrophy due to SEPN1 mutation presenting as cor pulmonale. Neurology 2005;64(2):395-6. PMID 15668457
104: Villar-Quiles RN, Catervi F, Cabet E, et al. ASC-1 is a cell cycle regulator associated with severe and mild forms of myopathy. Ann Neurol 2020;87(2):217-32. PMID 31794073
105: Voermans NC, Oldfors A, Jungbluth H. The congenital myopathies. Rosenberg's molecular and genetic basis of neurological and psychiatric disease. Elsevier, 2025:575-87.
106: Younger DS. Congenital myopathies. Handb Clin Neurol 2023;195:533-61.
107: Wallgren-Pettersson C, Bushby K, Mellies U, Simonds A. 117th ENMC workshop: ventilatory support in congenital neuromuscular disorders -- congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14(1):56-69. PMID 14659414
108: Wang CH, Dowling JJ, North K, et al. Consensus statement on standard of care for congenital myopathies. J Child Neurol 2012;27(3):363-82. PMID 22431881
109: Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010;20(10):2447-60. PMID 20422195
110: Wu S, Ibarra MC, Malicdan MC, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006;129:1470-80. PMID 16621918
111: Xu L, Wang Y, Yamaguchi N, Pasek DA, Meissner G. Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies. J Biol Chem 2008;283(10):6321-9. PMID 18171678
112: Zhang H, Chang M, Chen D, et al. Congenital myopathies: pathophysiological mechanisms and promising therapies. J Transl Med 2024;22(1):815. PMID 39223631
113: Zhou H, Brockington M, Jungbluth H, et al. Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. Am J Hum Genet 2006;79:859-68. PMID 17033962
114: Zhou H, Jungbluth H, Sewry CA, et al. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain 2007;130(Pt 8):2024-36. PMID 17483490

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Haluk Topaloglu MD

Dr. Topaloglu of Hacettepe Children's Hospital in Ankara, Turkey, has no relevant financial relationships to disclose.
See Profile
Bita Poorshiri MD

Dr. Poorshiri of Tabriz University of Medical Sciences has no relevant financial relationships to disclose.
See Profile

Editor

Harvey B Sarnat MS MD FRCPC

Dr. Sarnat of the University of Calgary has no relevant financial relationships to disclose.
See Profile

Former Authors

A Keith W Brownell MD
Monique M Ryan MD
Goknur Haliloglu MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor

autosomal dominant (typical)

autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Central core disease: G71.2

Minicore disease: G71.2

Multicore disease: G71.2

Malignant hyperthermia: T88.3
ICD-11: Central core disease: 8C72.02

Other specified congenital myopathy with structural abnormalities: 8C72.0Y

Malignant hyperthermia or hyperpyrexia: 8C78
OMIM: Central core disease of muscle: #117000

Selenoprotein N-SELENON: *606210

Multiminicore disease-external ophthalmoplegia: #255320

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Core myopathies

Associated Disorders

Congenital myopathies
Congenital muscular dystrophies
Hypertrophic cardiomyopathies
Malignant hyperthermia
Malignant hyperthermia susceptibility

Differential Diagnosis

congenital myopathies
minicore myopathy
nemaline myopathy
anterior horn cell disease
motor neuron disease
- hereditary peripheral neuropathies
- neuromuscular junction transmission defects
- muscular dystrophy
- myotonic dystrophy
- congenital muscular dystrophy
- infantile myotonic dystrophy
- metabolic myopathies
- motor neuron disease

Also Relevant

Congenital muscular dystrophies
Malignant hyperthermia
Neuromuscular pathology: overview
X-linked myotubular myopathy

Clinical Categories

Patient Handouts

Congenital myopathy

Web References

Testing

Central Core Disease

Core myopathies …

Core myopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Congenital Myopathy Causing Genes

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Choroid plexus tumors of childhood

Barth syndrome

Atlantoaxial dislocation

Congenital muscular dystrophy: merosin deficient form

Incontinentia pigmenti

Tuberous sclerosis complex

Fetal alcohol syndrome

Myoclonus epilepsy with ragged-red fibers

Core myopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Congenital Myopathy Causing Genes

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Choroid plexus tumors of childhood

Barth syndrome

Atlantoaxial dislocation

Congenital muscular dystrophy: merosin deficient form

Incontinentia pigmenti

Tuberous sclerosis complex

Fetal alcohol syndrome

Myoclonus epilepsy with ragged-red fibers

This is an article preview.
Start a Free Account
to access the full version.